| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
Oxygen carrier
|
|---|---|
| ln Vitro |
In addition to fatty acids, liver fatty acid binding protein (L-FABP) also interacts with ferriheme, which it binds with an affinity approximately one order of magnitude greater than that for oleic acid. We have, therefore, examined the effect of Ferroheme and ferriheme on the binding of oleate to rat L-FABP also called heme-binding protein. Both oxidation states of heme behaved as isosteric inhibitors for the binding of the fatty acid confirming a common binding site. The reduced form of heme (Fe(II)) is a threefold better competitor of oleate binding than ferriheme. To show whether the diffusion of heme would be affected by the presence of the binding protein, we measured the effect of the fatty acid binding protein on the diffusional flux of a water-soluble heme derivative, iron-deuteroporphyrin. The diffusional flux of iron-deuteroporphyrin did not change in the presence of the protein. This suggested that the binding affinity of fatty acid binding protein for iron-deuteroporphyrin is too great to allow rapid equilibrium between bound and unbound ligand across the system in an appropriate time frame [1].
|
| ln Vivo |
Ferroheme (cerebral hemorrhage model; Collagenase induction; Male SD rats (250-300g, 8 weeks old) induce oxidative stress by releasing iron ions, exacerbating nerve damage. Iron chelators can alleviate this damage [1]. Ferroheme (iron overload model; Intraperitoneal injection of FeSO?; C57BL/6 mice, 20-25g, 10 weeks old) resulted in upregulation of liver lipid peroxidation and iron death related genes, which can be reversed by antioxidants [2].
|
| References |
|
| Additional Infomation |
Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand.
Heme is a metabolite found in or produced by Escherichia coli (strain K12, MG1655). Heme is a metabolite found in or produced by Saccharomyces cerevisiae. Protoheme IX is a metabolite found in or produced by Saccharomyces cerevisiae. The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins. Drug Indication Used in the management of porphyria attacks, particularly in acute intermittent porphyria. |
| Molecular Formula |
C34H32FEN4O4
|
|---|---|
| Molecular Weight |
616.49
|
| Exact Mass |
616.177
|
| Elemental Analysis |
C, 66.24; H, 5.23; Fe, 9.06; N, 9.09; O, 10.38
|
| CAS # |
14875-96-8
|
| PubChem CID |
26945
|
| Appearance |
Brown to black Solid
|
| Boiling Point |
1122ºC at 760 mmHg
|
| Flash Point |
632.4ºC
|
| LogP |
2.322
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
43
|
| Complexity |
1010
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Fe+2].OC(CCC1=C(C)C2=CC3=C(C)C(C=C)=C(C=C4C(C)=C(C=C)C(C=C5C(C)=C(CCC(=O)O)C(=CC1=N2)[N-]5)=N4)[N-]3)=O |t:7,16,24,34|
|
| InChi Key |
KABFMIBPWCXCRK-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/C34H34N4O4.Fe/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;/h7-8,13-16H,1-2,9-12H2,3-6H3,(H4,35,36,37,38,39,40,41,42);/q;+2/p-2
|
| Chemical Name |
3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid;iron(2+)
|
| Synonyms |
heme; heme b; protoheme; heme; protoheme; 14875-96-8; Ferroheme; heme b; ferroprotoporphyrin; Reduced hematin; Haem; ferroprotoporphyrin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 10 mg/mL (16.22 mM)
1M NaOH: 1 mg/mL (1.62 mM) DMF: < 1 mg/mL DMSO: < 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6221 mL | 8.1104 mL | 16.2209 mL | |
| 5 mM | 0.3244 mL | 1.6221 mL | 3.2442 mL | |
| 10 mM | 0.1622 mL | 0.8110 mL | 1.6221 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Heme oxygenase (HO) activity in humans. Effects of heme arginate (Normosang®) on parameters of HO activity and on adenosine induced vasodilation.
CTID: null
Phase: Phase 2 Status: Prematurely Ended
Date: 2009-02-09
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
